Development and Function of Murine B Cells Lacking RANK

被引:42
作者
Perlot, Thomas [1 ]
Penninger, Josef M. [1 ]
机构
[1] Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria
基金
欧洲研究理事会;
关键词
BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; FAMILY-MEMBER; DENOSUMAB; OSTEOCLAST; TURNOVER; CANCER; OSTEOPETROSIS; RANKL/RANK; MUTATIONS;
D O I
10.4049/jimmunol.1102063
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
RANKL-RANK signaling regulates numerous physiologic processes such as bone remodeling, lymph node organogenesis, central thermoregulation, and formation of a lactating mammary gland in pregnancy. Recently, a receptor activator of NF-kappa B ligand (RANKL)-blocking Ab has been approved for human use in potentially millions of osteoporosis and cancer patients. However, germline deficiencies in RANKL or receptor activator of NF-kappa B (RANK) also lead to strong B cell defects in mice and human patients, suggesting that RANKL-RANK inhibition could interfere with B cell physiology and thereby trigger immunologic side-effects. To address this key question-that is, whether RANKL-RANK signaling affects B cell physiology directly or the observed defects are secondary because of the severe osteopetrosis-we generated B cell-specific RANK knockout mice. We show that B cells deficient for RANK undergo normal development and do not show any obvious defects in Ab secretion, class switch recombination, or somatic hypermutation. Our data indicate that ablation of the RANKL-RANK pathway has no direct adverse effect on B cell physiology. The Journal of Immunology, 2012, 188: 1201-1205.
引用
收藏
页码:1201 / 1205
页数:5
相关论文
共 26 条
[21]   RANK signals from CD4+3- inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla [J].
Rossi, Simona W. ;
Kim, Mi-Yeon ;
Leibbrandt, Andreas ;
Parnell, Sonia M. ;
Jenkinson, William E. ;
Glanville, Stephanie H. ;
McConnell, Fiona M. ;
Scott, Hamish S. ;
Penninger, Josef M. ;
Jenkinson, Eric J. ;
Lane, Peter J. L. ;
Anderson, Graham .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (06) :1267-1272
[22]   Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer [J].
Schramek, Daniel ;
Leibbrandt, Andreas ;
Sigl, Verena ;
Kenner, Lukas ;
Pospisilik, John A. ;
Lee, Heather J. ;
Hanada, Reiko ;
Joshi, Purna A. ;
Aliprantis, Antonios ;
Glimcher, Laurie ;
Pasparakis, Manolis ;
Khokha, Rama ;
Ormandy, Christopher J. ;
Widschwendter, Martin ;
Schett, Georg ;
Penninger, Josef M. .
NATURE, 2010, 468 (7320) :98-+
[23]   Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer [J].
Smith, Matthew R. ;
Egerdie, Blair ;
Toriz, Narciso Hernandez ;
Feldman, Robert ;
Tammela, Teuvo L. J. ;
Saad, Fred ;
Heracek, Jiri ;
Szwedowski, Maciej ;
Ke, Chunlei ;
Kupic, Amy ;
Leder, Benjamin Z. ;
Goessl, Carsten .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :745-755
[24]   Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL [J].
Sobacchi, Cristina ;
Frattini, Annalisa ;
Guerrini, Matteo M. ;
Abinun, Mario ;
Pangrazio, Alessandra ;
Susani, Lucia ;
Bredius, Robbert ;
Mancini, Grazia ;
Cant, Andrew ;
Bishop, Nick ;
Grabowski, Peter ;
Del Fattore, Andrea ;
Messina, Chiara ;
Errigo, Gabriella ;
Coxon, Fraser P. ;
Scott, Debbie I. ;
Teti, Anna ;
Rogers, Michael J. ;
Vezzoni, Paolo ;
Villa, Anna ;
Helfrich, Miep H. .
NATURE GENETICS, 2007, 39 (08) :960-962
[25]  
Tan W., 2011, Nature, V470, P548
[26]  
Yun TJ, 1998, J IMMUNOL, V161, P6113